The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia
- 14 November 2005
- Vol. 104 (12) , 2743-2752
- https://doi.org/10.1002/cncr.21535
Abstract
Clinical trials of monoclonal antibodies in combination with chemotherapy have reported previously unattained response rates in patients with B-cell chronic lymphocytic leukemia (B-CLL); however, the analysis of ZAP-70 protein and/or CD38 may explain better the discordant outcomes independent of treatmentKeywords
Funding Information
- Ministero del'Universitá e della Ricerca Scientifica e Tecnologica, Programmi di Ricerca di Interesse Nazionale, 2003
This publication has 37 references indexed in Scilit:
- Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood, 2001
- Rituximab Dose-Escalation Trial in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989
- A clinical staging system for chronic lymphocytic leukemia.Prognostic significanceCancer, 1977
- Clinical staging of chronic lymphocytic leukemiaBlood, 1975